News
Zacks Investment Research on MSN5d
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare DiseasesSanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...
Pharmaceutical Technology on MSN4d
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditionsSanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...
The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, ...
Sanofi has chalked up another win in a clinical trial of its oral BTK inhibitor rilzabrutinib, setting up regulatory filings in its first indication – rare disorder immune thrombocytopenia (ITP ...
US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a ...
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease ...
Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration (FDA) orphan drug designation (ODD) to treat two rare conditions ...
Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for the treatment of warm autoimmune hemolytic anemia (wAIHA) and IgG4 ...
With the application of Sanofi's TAILORED COVALENCY ® technology, rilzabrutinib can selectively inhibit the BTK target while potentially reducing the risk of off-target side effects. Based on its ...
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback